Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2020 from OUS - Section for Cellular Therapy

11 publications found

Bai B, Myklebust JH, Wälchli S (2020)
Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology
Methods Mol Biol, 2115, 445-454
DOI 10.1007/978-1-0716-0290-4_25, PubMed 32006416

Benard E, Casey NP, Inderberg EM, Wälchli S (2020)
SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy
Scand J Immunol, 92 (4), e12917
DOI 10.1111/sji.12917, PubMed 32557659

Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2020)
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Mol Ther (in press)
DOI 10.1016/j.ymthe.2020.11.019, PubMed 33212301

Dillard P, Lie M, Baken E, Lobert VH, Benard E, Köksal H, Inderberg EM, Wälchli S (2020)
Colorectal cysts as a validating tool for CAR therapy
BMC Biotechnol, 20 (1), 30
DOI 10.1186/s12896-020-00623-0, PubMed 32487146

Inderberg EM, Wälchli S (2020)
Sympathetic improvement of cancer vaccine efficacy
Hum Vaccin Immunother, 16 (8), 1888-1890
DOI 10.1080/21645515.2019.1703456, PubMed 31977269

Inderberg EM, Wälchli S (2020)
Long-term surviving cancer patients as a source of therapeutic TCR
Cancer Immunol Immunother, 69 (5), 859-865
DOI 10.1007/s00262-019-02468-9, PubMed 31915853

Kierulf-Vieira KS, Sandberg CJ, Waaler J, Lund K, Skaga E, Saberniak BM, Panagopoulos I, Brandal P, Krauss S, Langmoen IA, Vik-Mo EO (2020)
A Small-Molecule Tankyrase Inhibitor Reduces Glioma Stem Cell Proliferation and Sphere Formation
Cancers (Basel), 12 (6)
DOI 10.3390/cancers12061630, PubMed 32575464

Lichtenegger FS, Schnorfeil FM, Rothe M, Deiser K, Altmann T, Bücklein VL, Köhnke T, Augsberger C, Konstandin NP, Spiekermann K, Moosmann A, Boehm S, Boxberg M, Heemskerk MH, Goerlich D, Wittmann G, Wagner B, Hiddemann W, Schendel DJ, Kvalheim G, Bigalke I, Subklewe M (2020)
Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial
Clin Transl Immunology, 9 (3), e1117
DOI 10.1002/cti2.1117, PubMed 32153780

Wälchli S, Sioud M (2020)
Next Generation of Adoptive T Cell Therapy Using CRISPR/Cas9 Technology: Universal or Boosted?
Methods Mol Biol, 2115, 407-417
DOI 10.1007/978-1-0716-0290-4_22, PubMed 32006413

Weum Abrahamsen I, Grønvold BC, Inderberg EM, Mensali N, Mattsson J, Gedde-Dahl T (2020)
Posttransplantation Lymphoproliferative Disease Treated by Retransplantation
Case Reports Immunol, 2020, 9403123
DOI 10.1155/2020/9403123, PubMed 32158568

Winge-Main AK, Wälchli S, Inderberg EM (2020)
T cell receptor therapy against melanoma-Immunotherapy for the future?
Scand J Immunol, 92 (4), e12927
DOI 10.1111/sji.12927, PubMed 32640053

 
Page visits: 518568